Holen Sie sich die Stockscreener-App
6.65
1.74%
0.34
Exozymes Inc Aktie (EXOZ) Neueste Nachrichten
eXoZymes (EXOZ) Stock: Curia Deal Moves NCT Toward Commercial Production - Blockonomi
exozymes partners with Curia for NCT manufacturing scale-up - Investing.com
exozymes partners with Curia for NCT manufacturing scale-up By Investing.com - Investing.com India
eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT - Eagle-Tribune
A 3,000-employee manufacturer will help eXoZymes move a product toward larger-scale production. - Stock Titan
Exozymes CEO Michael Heltzen buys $6,405 in company stock By Investing.com - Investing.com South Africa
Exozymes (EXOZ) CEO adds stock with August buys and grant - Stock Titan
eXoZymes Inc. (EXOZ) Edges Lower, Holding Support at $6.13 After 0.77% DipNAAIM Exposure - dars.gov.et
eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO - Barchart.com
eXoZymes Provides Fourth Quarter and Full Year 2024 Update - Barchart.com
eXoZymes Inc. (EXOZ) Holds Near $7.17 as Shares Trade Within Established RangePut Dominated - vinanet.vn
Primer: eXoZymes (EXOZ US)Aug 2026 - Smartkarma
Exozymes (EXOZ) CSO adds 32,964 shares from RSU vesting - Stock Titan
eXoZymes (EXOZ): Ends Up by 10.00% at $7.04; Trading Range: the Near-Term Reference Band Stretches From $6.69 to $7.39 in the Available RecordKey Reversal Day - vinanet.vn
eXoZymes Q2FY26 Results: Net loss widens to $2.88M, raises $6M - scanx.trade
eXoZymes Q2 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: eXoZymes posts q2 2026 loss as launch plans advance - Investing.com
EXOZ: NCT program exceeded targets; $6M raised and $2M NIH grant secured for R&D and commercialization - TradingView
eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today - The Batesville Daily Guard
exoZymes reports 10-fold productivity gain in NCT manufacturing By Investing.com - Investing.com Canada
eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets - ACCESS Newswire
EXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets - marketscreener.com
exoZymes reports 10-fold productivity gain in NCT manufacturing - Investing.com
Will eXoZymes (NASDAQ:EXOZ) Spend Its Cash Wisely? - webull.com
eXoZymes Inc. (EXOZ) Drops 3% to $5.82, Pressuring Key Support at $5.53Narrow Range Breakout - vinanet.vn
MDB Capital Holdings (MDBH) records $16.1M H1 2026 loss and $33.1M eXoZymes stake - Stock Titan
EXOZYMES INC. 2Q 2026: Revenue $0 Net loss $(5.25M) — 10-Q Summary - TradingView
EXoZymes, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
eXoZymes Inc (EXOZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
eXoZymes Q2 Results: Update call scheduled for August 20 - scanx.trade
eXoZymes CEO to Lead Q2 Results Webinar With Q&A Aug. 20 - Stock Titan
eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026 - ACCESS Newswire
eXoZymes Inc. (EXOZ) Climbs 3.92% to $5.3 as Biotech Stock Approaches Key ResistancePut Spread Alert - dars.gov.et
eXoZymes Inc. (EXOZ) Gains 3.82% as Shares Approach Key Resistance at $5.57Upthrust Pattern - dars.gov.et
eXoZymes Inc (EXOZ) Stock News Today - TradingKey
eXoZymes Inc. (EXOZ) Slides 5.15% to $4.60 as Traders Eye Key Support at $4.37Turnaround Stocks - dars.gov.et
eXoZymes Inc. (EXOZ) Slips 1.1% as Shares Test Support Near $4.27Risk Reversal - vinanet.vn
eXoZymes Inc (EXOZ) Income Statement - TradingKey
eXoZymes Inc (EXOZ) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
eXoZymes Inc (EXOZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
eXoZymes Inc (EXOZ) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
eXoZymes Inc (EXOZ) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
EXOZ|eXoZymes Inc|Price:4.550|Chg%:-0.050 - TradingKey
eXoZymes Inc. Revenue Breakdown – NASDAQ:EXOZ - TradingView
EXOZ|eXoZymes Inc|Price:4.500|Chg%:-0.210 - TradingKey
eXoZymes Inc (EXOZ) Cash Flow - TradingKey
eXoZymes Inc (EXOZ) Balance Sheet - TradingKey
eXoZymes Inc (EXOZ) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
eXoZymes Inc (EXOZ) Institutional Confidence - TradingKey
eXoZymes Inc. (EXOZ) Slides Amid Biotech Volatility: Key Levels to WatchDay Trade Opportunities - dars.gov.et
eXoZymes, Inc. (EXOZ) Stock Price, News, Quote & History - Yahoo! Finance Canada
exoZymes selected for DOE Genesis Mission AI project By Investing.com - Investing.com Nigeria
exoZymes selected for DOE Genesis Mission AI project - Investing.com
EXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing - marketscreener.com
0.28%
4.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):